RxDoctor Payments DataLook up a doctor →

Rami Haddad, MD

Hematology & Oncology · Oak Lawn, ILNPI 1710072624

Payments from drug & device makers

$1,439,894in general payments, 2019–2025

Across 1,814 payments — averaging $793.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirati Therapeutics, Inc.$664K
  • Amgen$355K
  • AstraZeneca$88K
  • E.r. Squibb & Sons, L.L.C.$61K
  • Radius Health, Inc.$57K
  • Janssen Research & Development, LLC$54K
  • plus $160K from 54 others
$2,614in research payments, 2019–2025

Across 1 payment — averaging $2614.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mirati Therapeutics, Inc.177$664,308
Amgen77$355,027
AstraZeneca(2 entities)127$87,708
E.r. Squibb & Sons, L.L.C.103$60,696
Radius Health, Inc.43$57,275
Janssen Research & Development, LLC102$53,593
Merck112$24,726
Eli Lilly7$23,489
Jazz Pharmaceuticals Inc.22$17,160
Stemline Therapeutics Inc.9$14,383
Seagen Inc.27$14,032
Novartis135$12,319
Pfizer94$11,612
Sanofi US Services Inc.3$10,250
Astrazeneca UK Limited3$7,000
Janssen Scientific Affairs, LLC40$4,000
Regeneron Healthcare Solutions, Inc.55$3,160
Exelixis Inc.13$2,295
Rigel Pharmaceuticals, Inc.17$1,563
Johnson & Johnson(2 entities)82$1,375
Incyte Corporation48$1,198
Bayer18$1,195
Lilly USA, LLC27$966
Genentech USA, Inc.36$727
Gilead(2 entities)35$607
Takeda Pharmaceuticals U.S.A., Inc.27$558
Genentech, Inc.2$550
Beigene, Ltd.1$525
GSK23$520
Bristol Myers Squibb29$515
AbbVie26$489
Astellas Pharma US Inc23$447
Pharmacyclics LLC, An Abbvie Company24$424
Daiichi Sankyo Inc.20$416
Sanofi18$404
Eisai Inc.19$367
Array Biopharma Inc18$307
EMD Serono, Inc.15$294
Agios Pharmaceuticals, Inc.11$251
Global Blood Therapeutics, Inc.9$187
Puma Biotechnology, Inc.9$185
Blueprint Medicines Corporation7$175
Sobi, Inc4$139
Tersera Therapeutics LLC4$132
Taiho Oncology, Inc.6$132
Tempus AI, Inc6$129
Karyopharm Therapeutics Inc.5$117
Morphosys, US Inc.6$117
Boehringer Ingelheim6$112
Beone Medicines USA, Inc.3$108
G1 Therapeutics, Inc.5$101
Sumitomo Pharma America, Inc.4$87
Pharmacosmos Therapeutics Inc.3$81
Beigene USA, Inc.4$78
Ipsen Biopharmaceuticals, Inc4$75
Sanofi-aventis U.S. LLC1$65
Deciphera Pharmaceuticals Inc.3$62
Aurobindo Pharma USA, Inc.3$56
Tactile Systems Technology Inc2$53
Servier Pharmaceuticals LLC3$53

How this compares

$1,439,894 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024
$4,428,847
Medicare patients
557
Services billed
160,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Oak Lawn

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →